海思科(002653.SZ)与Nuvectis签署HSK42360和HSK39297授权许可协议

智通财经06-23

智通财经APP讯，海思科(002653.SZ)发布公告，公司与美国Nuvectis Pharma,Inc.(以下简称“Nuvectis”)于近日签订独占许可协议，授予Nuvectis在除大中华区域以外的全球范围内开发、生产和商业化HSK42360项目(BRAF抑制剂)的独家权利，以及在除大中华、东南亚及印度以外区域的全球范围内开发、生产和商业化HSK39297项目(CFB抑制剂)的独家权利。作为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2645006020?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-23 08:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645006020","market":"hk","top_or_hot":-1,"title":"海思科(002653.SZ)与Nuvectis签署HSK42360和HSK39297授权许可协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，海思科(002653.SZ)发布公告，公司与美国Nuvectis Pharma,Inc.(以下简称“Nuvectis”)于近日签订独占许可协议，授予Nuvectis在除大中华区域以外的全球范围内开发、生产和商业化HSK42360项目(BRAF抑制剂)的独家权利，以及在除大中华、东南亚及印度以外区域的全球范围内开发、生产和商业化HSK39297项目(CFB抑制剂)的独家权利。作为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457299.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海思科(002653.SZ)与Nuvectis签署HSK42360和HSK39297授权许可协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海思科(002653.SZ)与Nuvectis签署HSK42360和HSK39297授权许可协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-23 08:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1457299.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，海思科(002653.SZ)发布公告，公司与美国Nuvectis Pharma,Inc.(以下简称“Nuvectis”)于近日签订独占许可协议，授予Nuvectis在除大中华区域以外的全球范围内开发、生产和商业化HSK42360项目(BRAF抑制剂)的独家权利，以及在除大中华、东南亚及印度以外区域的全球范围内开发、生产和商业化HSK39297项目(CFB抑制剂)的独家权利。作为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457299.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1457299.html","article_id":"2645006020","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645006020","pubTimestamp":1782175672,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，海思科 发布公告，公司与美国Nuvectis Pharma,Inc.于近日签订独占许可协议，授予Nuvectis在除大中华区域以外的全球范围内开发、生产和商业化HSK42360项目的独家权利，以及在除大中华、东南亚及印度以外区域的全球范围内开发、生产和商业化HSK39297项目的独家权利。作为对外许可交易对价的一部分，公司将从Nuvectis获得HSK42360和HSK39297项目的授权许可费以及销售提成。目前，HSK42360正在开展I期临床研究。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0188":"融资融券","BK4139":"生物科技","BK0077":"质押式回购","BK0033":"西藏振兴","BK0028":"国家队","BK0239":"医药制造","002653":"海思科","NVCT":"Nuvectis Pharma, Inc."},"translate_title":"HiSco (002653.SZ) Inks License Agreement with Nuvectis for HSK42360 and HSK39297 Licensing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCT":1.5,"002653":1.5},"content_text":"智通财经APP讯，海思科(002653.SZ)发布公告，公司与美国Nuvectis Pharma,Inc.(以下简称“Nuvectis”)于近日签订独占许可协议，授予Nuvectis在除大中华区域以外的全球范围内开发、生产和商业化HSK42360项目(BRAF抑制剂)的独家权利，以及在除大中华、东南亚及印度以外区域的全球范围内开发、生产和商业化HSK39297项目(CFB抑制剂)的独家权利。作为对外许可交易对价的一部分，公司将从Nuvectis获得HSK42360和HSK39297项目的授权许可费(包括4,000万美元的首付款和近期里程碑付款及最高14.21亿美元的额外里程碑付款)以及销售提成。HSK42360是公司自主研发的一种同类最佳BRAF paradoxical breaker抑制剂，可在抑制BRAF V600X突变的同时阻断BRAF二聚体形成，从而克服第一代BRAF抑制剂在多种肿瘤治疗中出现的获得性耐药问题。该分子具有良好的中枢神经系统渗透性，在原发性脑肿瘤及脑转移瘤中均显示出较强的潜在治疗优势。目前，HSK42360正在开展I期临床研究。HSK39297是公司自主研发的一种高效的选择性补体B因子(FB)小分子抑制剂，通过抑制FB活性从而阻断旁路途径(AP)的激活与补体扩增循环，进而抑制整个补体通路的活性，旨在治疗由补体异常活化所介导的多种疾病。目前，HSK39297已在中国递交PNH适应症的新药上市申请(NDA)，并正在开展狼疮肾炎患者的Ⅱ期临床试验和原发性IgA肾病Ⅲ期临床研究。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645006020","isCrawlerRequest":true}